Nabriva Therapeutics plc NBRV
At closeJul 31, 2023, 4:00 PM EDT
52-week range unavailable
- Market cap
- 4.96M
- Revenue (ttm)
- 36.51M
- Profit margin
- -148.11%
- Shares out
- 3.20M
- Forward P/E
- -0.18
- Volume
- 706.54K
- Open
- 1.45
- Previous close
- 1.42
- Day's range
- 1.35 – 1.90
- Beta
- 1.55
- Analysts
- Underperform
- Earnings date
- Aug 2, 2023
2Y -31.33 (-95.66%)
Key statistics
- Enterprise value
- 3.59M
- PEG ratio
- 0.00
- Price / sales
- 0.14
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -5.40%
- Free cash flow
- -2.61M
- Total cash
- 1.80M
- Total debt
- 542.00K
- Return on equity
- -268.53%
- Short % of float
- 1.64%
- 50-day average
- 1.57
- 200-day average
- 1.83
Analyst view
Consensus: underperform
- Strong buy2
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 2, 2023
Expected Aug 2, 2023. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 2, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 22, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Apr 17, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | -4.03 | — | — | — |
| Aug 3, 2022 | Jun 1, 2022 | -5.00 | — | — | — |
| May 5, 2022 | Mar 1, 2022 | -4.75 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 7, 2020 | Morgan Stanley | main | — | Equal-Weight |
| Apr 9, 2020 | H.C. Wainwright | down | Buy | Neutral |
| Apr 9, 2020 | HC Wainwright & Co. | down | Buy | Neutral |
| Apr 8, 2020 | Needham | down | Buy | Hold |
| Mar 19, 2020 | Wedbush | down | Outperform | Neutral |
| Mar 17, 2020 | Morgan Stanley | down | Overweight | Equal-Weight |
About Nabriva Therapeutics plc
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Ireland
- Website
- nabriva.com
News
Aadi Bioscience (NASDAQ:AADI) versus Nabriva Therapeutics (NASDAQ:NBRV) Head-To-Head Analysis 
Nabriva Therapeutics (NASDAQ:NBRV) versus Virpax Pharmaceuticals (NASDAQ:VRPX) Head-To-Head Contrast 
7 Stocks to Sell as Banks Melt Down 
Stocks That Hit 52-Week Lows On Monday 
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session 
Stocks That Hit 52-Week Lows On Friday 
Stocks That Hit 52-Week Lows On Friday 
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study 
Nabriva's stock is up after sharing antibiotic news 
Nabriva Therapeutics plc (NBRV) Q3 2022 Earnings Call Transcript
Your note
Sign in to keep a note on NBRV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BROOM COLIN | Director | Sale | Aug 1, 2022 | 36,523 |
| BURGESS DANIEL D | Director | Sale | Aug 1, 2022 | 10,384 |
| CORRIGAN MARK | Director | Sale | Aug 1, 2022 | 7,203 |
| DOLAN DANIEL | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 10, 2022 | 0 |
| GELONE STEVEN P | President | Conversion of Exercise of derivative security | Aug 10, 2022 | 0 |
| GUICO-PABIA CHRISTINE J | Officer | Conversion of Exercise of derivative security | Aug 10, 2022 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Values First Advisors, Inc. | 0.83% | 26,682 | 41.36K | Mar 30, 2023 |
| Renaissance Technologies, LLC | 0.73% | 23,361 | 36.21K | Mar 30, 2023 |
| Frazier Life Sciences Management, L.P. | 0.53% | 17,025 | 26.39K | Mar 30, 2023 |
| Citadel Advisors Llc | 0.36% | 11,607 | 17.99K | Mar 30, 2023 |
| Morgan Stanley | 0.13% | 4,108 | 6.37K | Mar 30, 2023 |
| Advisor Group Holdings, Inc. | 0.06% | 2,008 | 3.11K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 1,709 | 2.65K | Feb 27, 2023 |